[1] World Health Organization. Global tuberculosis report. 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf. [2021-2-7].https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
[2] Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363(11):1005 − 15. http://dx.doi.org/10.1056/NEJMoa0907847CrossRef
[3] Nikam C, Jagannath M, Narayanan MM, Ramanabhiraman V, Kazi M, Shetty A, et al. Rapid diagnosis of Mycobacterium tuberculosis with truenat MTB: a near-care approach. PLoS One 2013;8(1):e51121. http://dx.doi.org/10.1371/journal.pone.0051121CrossRef
[4] Naidoo P, Theron G, Rangaka MX, Chihota VN, Vaughan L, Brey ZO, et al. The South African tuberculosis care cascade: estimated losses and methodological challenges. J Infect Dis 2017;216(S7):S702 − 13. http://dx.doi.org/10.1093/infdis/jix335CrossRef
[5] Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371(8):723 − 32. http://dx.doi.org/10.1056/NEJMoa1313865CrossRef
[6] Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe 2020;1(4):e165 − 74. http://dx.doi.org/10.1016/S2666-5247(20)30031-8CrossRef
[7] Gupta R, Gao MQ, Cirule A, Xiao HP, Geiter LJ, Wells CD. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015;373(3):291 − 2. http://dx.doi.org/10.1056/NEJMc1415332CrossRef
[8] Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015;385(9979):1738 − 47. http://dx.doi.org/10.1016/S0140-6736(14)62002-XCrossRef
[9] Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367(16):1508 − 18. http://dx.doi.org/10.1056/NEJMoa1201964CrossRef
[10] Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020;382(10):893 − 902. http://dx.doi.org/10.1056/NEJMoa1901814CrossRef
[11] Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother 2019;63(5):e00021 − 19. http://dx.doi.org/10.1128/AAC.00021-19CrossRef
[12] Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 2018;379(2):138 − 49. http://dx.doi.org/10.1056/NEJMoa1714021CrossRef
[13] Tait DR, Hatherill M, van der Meeren O, Ginsberg AM, van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 2019;381(25):2429 − 39. http://dx.doi.org/10.1056/NEJMoa1909953CrossRef